Redeye: Enea - Big Steps on the Turnaround Journey
Redeye states the Q3 report is a good data point that the profitability "turn-around" story is underway, with OPEX well under our estimates. While organic growth is still lack-luster, the EBITDA-margin is on track to reach the company’s 35% target set out in the Q4 2022 report. Redeye makes a slight upwards revision to its fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/